A new cannabis-based cancer drug called Cialis is being used by Israel’s health authorities to treat a new strain of cancer that causes the tumors to grow in a similar way to the original tumor, a new study shows.
The drug, known as Cialus, is being tested on patients with a rare type of cancer called sarcoma sarcomas.
The drug, called Cinalis, is a cancer treatment for sarcomatous sarcomae.
The cancerous tumors are a type of sarcomoma that can grow in small areas, making them hard to treat with conventional chemotherapy.
Cialis, which was developed by Israel-based biotech firm, Novartis, will treat the patients with metastatic sarcomomas, the Israeli Medical Association said on its website.
The cancer is an aggressive form of cancer.
The new drug has also been shown to significantly reduce side effects, according to the research.
Coralis, developed by Novartes, is made by combining a cannabinoid called THC, which is known to be highly effective at killing cancer cells, and a chemical called CBN.
It was first developed in 2013, but has been under development for at least a decade.
A cannabinoid is a substance that has a high level of cannabinoids, a group of compounds that includes the active ingredient, tetrahydrocannabinol (THC).
THC is an ingredient in marijuana, which has been used in recreational and medical marijuana products for decades.
The compound CBN is an active ingredient in a number of cancer treatments.
It is a derivative of cannabidiol (CBD), a compound that is found in cannabis plants.CBD is a cannabinoid that has been shown in a variety of cancer drugs to be effective in treating certain cancers.
It has also proven effective in other cancers, including colon cancer.
Cralis is the first cannabis-derived cancer drug approved for use in Israel, and is being studied by Israel Cancer Research Institute researchers and Israeli authorities.
It’s a novel approach to treat the cancerous growths, said Dr. Shira Tzur, an expert on cancer at the Hebrew University.
Cranial tumors are the most common type of skin cancer in the United States, according the National Cancer Institute.
The FDA has not yet approved Cialos for sale in the U.S. The FDA has yet to say when it will make a final decision on the drug’s application for a special drug license, but the agency said it will be ready to grant it.
Cials was first approved in Europe in 2016 and in other European countries in 2020.
The Israeli government is trying to make sure the drug is safe for people who are exposed to cannabis, including those who smoke it.
Cancer patients should not use the drug if they have already received chemotherapy, the agency added.
The agency is working to make the drug more widely available, said Tzoor.
The Drug Enforcement Administration will not approve the drug for use outside of the U-20 and U-30 age groups.
Cinalis is also being tested against other rare types of cancer, including melanoma and multiple myeloma.
The first clinical trials for Ciales are planned for this year.